S32
VC Fund
San Diego, United States
S32 is a VC fund in San Diego focused on Health Care and Biotechnology. S32 the new venture fund launched by Bill Maris, was named in homage to Section 31, an intelligence agency from the Star Trek universe.Maris, the GV (Google Ventures) founder/former-CEO, has raised $150 million for the project that will focus on various investments.The fund will be run directly by Maris and primarily based out of SanDiego.
- Total investments:
- 194
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $414M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries S32 invests in
Stages S32 invests in
Countries S32 invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Investment Focus
Industry
- Health Care 46 (24%)
- Biotechnology 43 (22%)
- Artificial Intelligence 31 (16%)
- Machine Learning 19 (10%)
- Medical 18 (9%)
Stage
- Series B 45 (23%)
- Series A 40 (21%)
- Series C 19 (10%)
- Seed 17 (9%)
- Series D 9 (5%)
Country
- United States 95 (49%)
- United Kingdom 3 (2%)
- Israel 2 (1%)
- India 1 (1%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Harrison
Managing Partner and CEO
|
Managing Partner and CEO | Total investments: 17 | Find email | |
Bill Maris
Founder
|
Founder | Total investments: 24 | Find email | |
Jennifer Kercher
COO and General Counsel
|
COO and General Counsel | Total investments: 0 | Find email | |
Jonathan Faerber
CFO
|
CFO | Total investments: 0 | Find email | |
Lindsey Acharya
Chief of Staff and Executive Assistant
|
Chief of Staff and Executive Assistant | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatmentsfor patients suffering from today’s most challenging diseases. | $75M / Series C / Sep 24, 2026 | ||
| Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global geneticbiodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most. | $140M / Series C / Sep 23, 2026 | ||
| Ema is developing next-generation AI technologies to help every employee in the workplace be their most creative and productive. Ema is a seamless, accurate, and secure Enterprise Generative AI system that simplifies complex tasks using enterprise tools. | $77M / Series B / Sep 23, 2026 | ||
| Snorkel AI is a technology startup that empowers data scientists and developers to turn data into accurate and adaptable AI applications fast with Snorkel Flow, a first-of-its-kind data-centric development platform, powered by programmatic labeling. Snorkel Flow reduces the time, cost, and friction of labeling training data so data science anddevelopment teams can more easily build and scale AI models to deploy more meaningful applications. Incorporating human judgment into the AI process through subject-matter experts is made more efficient and scalable leading to more ethical, responsible outcomes.Two out of the top three US banks, several government agencies and Fortune 500 companies use Snorkel Flow. Snorkel’s core research was developed at Stanford AI lab and is deployed at Google, Intel, Apple, IBM, DARPA, and other trailblazing organizations. | $350M / Series E / Sep 22, 2026 | ||
| SciFin is an AI-powered revenue intelligence platform designed to close the “context gap” faced by modern revenue teams. Sales information is often scattered across CRM systems, emails, call notes, documents, spreadsheets, people, and multiple AI tools. SciFin brings this information together to create a more complete and current view of deals,accounts, representatives, pipelines, and territories. The platform helps sales leaders and revenue operations teams identify at-risk deals earlier, improve forecasting, understand rep and pipeline performance, and reduce the time spent manually collecting and reconciling information. Sales managers can use the resulting context to focus coaching where it matters most, while sales representatives can quickly understand account history, risks, open questions, and next steps before customer meetings. | $44M / Seed / Sep 01, 2026 | ||
| Empirik develops an AI infrastructure agent that maps the blast radius and operational impact of configuration, infrastructure, and code updates across cloud and on-premises environments before they are deployed. | $21M / Seed / Sep 01, 2026 | ||
| Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value. | $37.3M / Series B / Aug 26, 2026 | ||
| Linear allows the user to manage software development and track bugs. Built for speed and efficiency.The founders started Linear from their own frustrations building software projects in successful high-growth companies like Airbnb, Coinbase and Uber. The founders wanted to create the tools that focus us and its team in making progress, not getin the way. Tools that are fast and efficient. Speed and performance were the main things Linear focuses on early on and keep focusing on that. | $99M / Secondary Market / Aug 26, 2026 | ||
| Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $50M / Venture - Series Unknown / Aug 19, 2026 | ||
| Whatnot is a Los Angeles-based startup that creates a place where avid collectors could come together over shared interests. Whatnot is a marketplace to buy and sell authentic collectible items. Whatnot was founded in 2019, in California. | $547M / Series G / Aug 06, 2026 | ||
| See all 194 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does S32 invest in?
S32 invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 194 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact S32?
Public channels for S32 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at S32?
The team at S32 includes Andrew Harrison (Managing Partner and CEO), Bill Maris (Founder) and Jennifer Kercher (COO and General Counsel), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
